Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms
- 4 April 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 121 (14) , 2725-2733
Abstract
Leukemic transformation (LT) is a rare but fatal complication of Philadelphia-negative myeloproliferative neoplasms (MPNs) for which optimal treatment strategies are not known. At our center, we have adopted a treatment approach for LT where patients within the transplant age group who have a reasonable fitness level are treated with curative intent and offered induction chemotherapy. Subsequently, those who respond and have a suitable donor are considered for allogeneic hematopoietic cell transplantation (HCT). In this study, we evaluated the clinical outcomes of this treatment approach in 75 patients with LT. The 2-year overall survival (OS) from the time of LT was 15%. A total of 39 patients (52%) were treated with curative intent (induction ± HCT) and had a 2-y OS of 26% compared with 3% in those noncuratively treated (P < .0001). In the curative intent group, 18 individuals (46%) achieved complete remission (CR) or CR with incomplete recovery and 12 (31%) reverted to a chronic MPN phase, with 17 patients undergoing HCT. Survival of patients posttransplant was significantly improved compared with those who responded to induction but were not transplanted (2-y OS of 47% vs 15%; P = .03). Thus, induction chemotherapy followed by HCT has the potential for long-term disease control in select patients with LT preceded by a MPN.Keywords
This publication has 20 references indexed in Scilit:
- Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phaseLeukemia Research, 2012
- Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?Current Hematologic Malignancy Reports, 2011
- Myeloid blastic transformation of myeloproliferative neoplasms—A review of 112 casesLeukemia Research, 2011
- Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)Blood, 2010
- Therapeutic options for patients with myelofibrosis in blast phaseLeukemia Research, 2010
- Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic TransformationTransplantation and Cellular Therapy, 2010
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesBlood, 2009
- The natural history and treatment outcome of blast phase BCR-ABL− myeloproliferative neoplasmsBlood, 2008
- Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatmentLeukemia, 2007
- Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 casesBlood, 2005